New

Immuno-Oncology Drugs Market

2021

Immuno-Oncology Drugs Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Drug Type (Immune Checkpoint Inhibitors, Monoclonal Antibodies, Cytokine Based Immunotherapy, Cancer Vaccines, CAR-T Cell Therapy); Therapeutic Application (Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Prostate Cancer, Bladder Cancer, Others); End User (Hospitals, Clinics, Ambulatory Surgical Centers) and Geography

| Report Code: TIPRE00004055 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming

Market Insights

Immuno-Oncology Drugs Market 2028 By Drug Type, Therapeutic Application, End User and Geography | The Insight Partners

Covid
Assesing the covid-19 impact?
Get the Latest COVID-19 Analysis on this market
Request Now
Happy to join you in your fight against the COVID-19 economic pandemic!

MARKET OVERVIEW



Immuno-oncology, also called as cancer immunotherapy is a biologic treatment, which boosts the body's natural defenses to resist the growth of cancer. This therapy utilizes constituents made by the body or in a research laboratory to reestablish or improve the immune system function. Immuno-oncology is a cutting-edge cancer research technique that aims to use the body's own immune system to fight cancer cells. The world is currently at the forefront of this field, with many substances under development for use in a variety of malignancies, as well as an approved immuno-oncology drug which is still being investigated for novel applications.

MARKET SCOPE



The "Global Immuno-Oncology Drugs Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of the immuno-oncology drugs market with detailed market segmentation by drug type, therapeutic application and end user. The report provides key statistics on the market status of the leading immuno-oncology drugs market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION



  • Based on drug type the market is segmented as, immune checkpoint inhibitors, monoclonal antibodies, cytokine based immunotherapy, cancer vaccines, Car-T cell therapy.
  • Based on therapeutic application the market is segmented as, melanoma, lung cancer, blood cancer, renal cell carcinoma, prostate cancer, bladder cancer, others.
  • Based on end user the market is segmented as, hospitals, clinics, ambulatory surgical centers.

MARKET DYNAMICS


Drivers:



  • Growing prevalence of cancers across the globe is the key driving factor for the market growth.
  • Rising adoption of immuno therapy drugs to manage malignancies.
  • Extensive R&D activities to develop and lauch more targeted therapies for management of cancers and malignancies.

Restraints:



  • However, high cost associated with the therapy is expected to restrain market growth during the forecast period.

REGIONAL FRAMEWORK



The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The immuno-oncology drugs market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.
The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the immuno-oncology drugs market in these regions.

IMPACT OF COVID-19 ON IMMUNO-ONCOLOGY DRUGS MARKET



COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. Shutdown of various plants and factories has affected the global supply chains and negatively impacted the manufacturing, delivery schedules, and sales of products in global market. Few companies have already announced possible delays in product deliveries and slump in future sales of their products. According to the current market situation, the report further assesses the present and future effects of the COVID-19 pandemic on the overall market, giving more reliable and authentic projections In addition to this, the global travel bans imposed by countries in Europe, Asia-Pacific, and North America are affecting the business collaborations and partnerships opportunities.

MARKET PLAYERS



The report covers key developments in the immuno-oncology drugs market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the marketwere acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market payers from immuno-oncology drugs market are anticipated to lucrative growth opportunities in the future with the rising demand for immuno-oncology drugs in the global market.
The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the immuno-oncology drugs market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.
  • Amgen, Inc.
  • AstraZeneca
  • Bristol-Myers Squibb Company
  • Lilly
  • Sanofi
  • F. Hoffmann-La Roche
  • Novartis AG
  • AbbVie, Inc.
  • Pfizer Inc.
  • Merck KGaA,
    The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.
  • TABLE OF CONTENTS

    1. INTRODUCTION
    1.1. SCOPE OF THE STUDY
    1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
    1.3. MARKET SEGMENTATION
    1.3.1 Immuno-Oncology Drugs Market - By Drug Type
    1.3.2 Immuno-Oncology Drugs Market - By Therapeutic Application
    1.3.3 Immuno-Oncology Drugs Market - By End User
    1.3.4 Immuno-Oncology Drugs Market - By Region
    1.3.4.1 By Country

    2. KEY TAKEAWAYS

    3. RESEARCH METHODOLOGY

    4. IMMUNO-ONCOLOGY DRUGS MARKET LANDSCAPE
    4.1. OVERVIEW
    4.2. PORTER'S FIVE FORCES ANALYSIS
    4.2.1 Bargaining Power of Buyers
    4.2.1 Bargaining Power of Suppliers
    4.2.1 Threat of Substitute
    4.2.1 Threat of New Entrants
    4.2.1 Competitive Rivalry
    4.3. EXPERT OPINIONS

    5. IMMUNO-ONCOLOGY DRUGS MARKET - KEY MARKET DYNAMICS
    5.1. KEY MARKET DRIVERS
    5.2. KEY MARKET RESTRAINTS
    5.3. KEY MARKET OPPORTUNITIES
    5.4. FUTURE TRENDS
    5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS

    6. IMMUNO-ONCOLOGY DRUGS MARKET - GLOBAL MARKET ANALYSIS
    6.1. IMMUNO-ONCOLOGY DRUGS - GLOBAL MARKET OVERVIEW
    6.2. IMMUNO-ONCOLOGY DRUGS - GLOBAL MARKET AND FORECAST TO 2028
    6.3. MARKET POSITIONING/MARKET SHARE

    7. IMMUNO-ONCOLOGY DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - DRUG TYPE
    7.1. OVERVIEW
    7.2. DRUG TYPE MARKET FORECASTS AND ANALYSIS
    7.3. IMMUNE CHECKPOINT INHIBITORS
    7.3.1. Overview
    7.3.2. Immune Checkpoint Inhibitors Market Forecast and Analysis
    7.4. MONOCLONAL ANTIBODIES
    7.4.1. Overview
    7.4.2. Monoclonal Antibodies Market Forecast and Analysis
    7.5. CYTOKINE BASED IMMUNOTHERAPY
    7.5.1. Overview
    7.5.2. Cytokine Based Immunotherapy Market Forecast and Analysis
    7.6. CANCER VACCINES
    7.6.1. Overview
    7.6.2. Cancer Vaccines Market Forecast and Analysis
    7.7. CAR-T CELL THERAPY
    7.7.1. Overview
    7.7.2. CAR-T Cell Therapy Market Forecast and Analysis
    8. IMMUNO-ONCOLOGY DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - THERAPEUTIC APPLICATION
    8.1. OVERVIEW
    8.2. THERAPEUTIC APPLICATION MARKET FORECASTS AND ANALYSIS
    8.3. MELANOMA
    8.3.1. Overview
    8.3.2. Melanoma Market Forecast and Analysis
    8.4. LUNG CANCER
    8.4.1. Overview
    8.4.2. Lung Cancer Market Forecast and Analysis
    8.5. BLOOD CANCER
    8.5.1. Overview
    8.5.2. Blood Cancer Market Forecast and Analysis
    8.6. RENAL CELL CARCINOMA
    8.6.1. Overview
    8.6.2. Renal Cell Carcinoma Market Forecast and Analysis
    8.7. PROSTATE CANCER
    8.7.1. Overview
    8.7.2. Prostate Cancer Market Forecast and Analysis
    8.8. BLADDER CANCER
    8.8.1. Overview
    8.8.2. Bladder Cancer Market Forecast and Analysis
    8.9. OTHERS
    8.9.1. Overview
    8.9.2. Others Market Forecast and Analysis
    9. IMMUNO-ONCOLOGY DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - END USER
    9.1. OVERVIEW
    9.2. END USER MARKET FORECASTS AND ANALYSIS
    9.3. HOSPITALS
    9.3.1. Overview
    9.3.2. Hospitals Market Forecast and Analysis
    9.4. CLINICS
    9.4.1. Overview
    9.4.2. Clinics Market Forecast and Analysis
    9.5. AMBULATORY SURGICAL CENTERS
    9.5.1. Overview
    9.5.2. Ambulatory Surgical Centers Market Forecast and Analysis

    10. IMMUNO-ONCOLOGY DRUGS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
    10.1. NORTH AMERICA
    10.1.1 North America Immuno-Oncology Drugs Market Overview
    10.1.2 North America Immuno-Oncology Drugs Market Forecasts and Analysis
    10.1.3 North America Immuno-Oncology Drugs Market Forecasts and Analysis - By Drug Type
    10.1.4 North America Immuno-Oncology Drugs Market Forecasts and Analysis - By Therapeutic Application
    10.1.5 North America Immuno-Oncology Drugs Market Forecasts and Analysis - By End User
    10.1.6 North America Immuno-Oncology Drugs Market Forecasts and Analysis - By Countries
    10.1.6.1 United States Immuno-Oncology Drugs Market
    10.1.6.1.1 United States Immuno-Oncology Drugs Market by Drug Type
    10.1.6.1.2 United States Immuno-Oncology Drugs Market by Therapeutic Application
    10.1.6.1.3 United States Immuno-Oncology Drugs Market by End User
    10.1.6.2 Canada Immuno-Oncology Drugs Market
    10.1.6.2.1 Canada Immuno-Oncology Drugs Market by Drug Type
    10.1.6.2.2 Canada Immuno-Oncology Drugs Market by Therapeutic Application
    10.1.6.2.3 Canada Immuno-Oncology Drugs Market by End User
    10.1.6.3 Mexico Immuno-Oncology Drugs Market
    10.1.6.3.1 Mexico Immuno-Oncology Drugs Market by Drug Type
    10.1.6.3.2 Mexico Immuno-Oncology Drugs Market by Therapeutic Application
    10.1.6.3.3 Mexico Immuno-Oncology Drugs Market by End User
    10.2. EUROPE
    10.2.1 Europe Immuno-Oncology Drugs Market Overview
    10.2.2 Europe Immuno-Oncology Drugs Market Forecasts and Analysis
    10.2.3 Europe Immuno-Oncology Drugs Market Forecasts and Analysis - By Drug Type
    10.2.4 Europe Immuno-Oncology Drugs Market Forecasts and Analysis - By Therapeutic Application
    10.2.5 Europe Immuno-Oncology Drugs Market Forecasts and Analysis - By End User
    10.2.6 Europe Immuno-Oncology Drugs Market Forecasts and Analysis - By Countries
    10.2.6.1 Germany Immuno-Oncology Drugs Market
    10.2.6.1.1 Germany Immuno-Oncology Drugs Market by Drug Type
    10.2.6.1.2 Germany Immuno-Oncology Drugs Market by Therapeutic Application
    10.2.6.1.3 Germany Immuno-Oncology Drugs Market by End User
    10.2.6.2 France Immuno-Oncology Drugs Market
    10.2.6.2.1 France Immuno-Oncology Drugs Market by Drug Type
    10.2.6.2.2 France Immuno-Oncology Drugs Market by Therapeutic Application
    10.2.6.2.3 France Immuno-Oncology Drugs Market by End User
    10.2.6.3 Italy Immuno-Oncology Drugs Market
    10.2.6.3.1 Italy Immuno-Oncology Drugs Market by Drug Type
    10.2.6.3.2 Italy Immuno-Oncology Drugs Market by Therapeutic Application
    10.2.6.3.3 Italy Immuno-Oncology Drugs Market by End User
    10.2.6.4 Spain Immuno-Oncology Drugs Market
    10.2.6.4.1 Spain Immuno-Oncology Drugs Market by Drug Type
    10.2.6.4.2 Spain Immuno-Oncology Drugs Market by Therapeutic Application
    10.2.6.4.3 Spain Immuno-Oncology Drugs Market by End User
    10.2.6.5 United Kingdom Immuno-Oncology Drugs Market
    10.2.6.5.1 United Kingdom Immuno-Oncology Drugs Market by Drug Type
    10.2.6.5.2 United Kingdom Immuno-Oncology Drugs Market by Therapeutic Application
    10.2.6.5.3 United Kingdom Immuno-Oncology Drugs Market by End User
    10.2.6.6 Rest of Europe Immuno-Oncology Drugs Market
    10.2.6.6.1 Rest of Europe Immuno-Oncology Drugs Market by Drug Type
    10.2.6.6.2 Rest of Europe Immuno-Oncology Drugs Market by Therapeutic Application
    10.2.6.6.3 Rest of Europe Immuno-Oncology Drugs Market by End User
    10.3. ASIA-PACIFIC
    10.3.1 Asia-Pacific Immuno-Oncology Drugs Market Overview
    10.3.2 Asia-Pacific Immuno-Oncology Drugs Market Forecasts and Analysis
    10.3.3 Asia-Pacific Immuno-Oncology Drugs Market Forecasts and Analysis - By Drug Type
    10.3.4 Asia-Pacific Immuno-Oncology Drugs Market Forecasts and Analysis - By Therapeutic Application
    10.3.5 Asia-Pacific Immuno-Oncology Drugs Market Forecasts and Analysis - By End User
    10.3.6 Asia-Pacific Immuno-Oncology Drugs Market Forecasts and Analysis - By Countries
    10.3.6.1 Australia Immuno-Oncology Drugs Market
    10.3.6.1.1 Australia Immuno-Oncology Drugs Market by Drug Type
    10.3.6.1.2 Australia Immuno-Oncology Drugs Market by Therapeutic Application
    10.3.6.1.3 Australia Immuno-Oncology Drugs Market by End User
    10.3.6.2 China Immuno-Oncology Drugs Market
    10.3.6.2.1 China Immuno-Oncology Drugs Market by Drug Type
    10.3.6.2.2 China Immuno-Oncology Drugs Market by Therapeutic Application
    10.3.6.2.3 China Immuno-Oncology Drugs Market by End User
    10.3.6.3 India Immuno-Oncology Drugs Market
    10.3.6.3.1 India Immuno-Oncology Drugs Market by Drug Type
    10.3.6.3.2 India Immuno-Oncology Drugs Market by Therapeutic Application
    10.3.6.3.3 India Immuno-Oncology Drugs Market by End User
    10.3.6.4 Japan Immuno-Oncology Drugs Market
    10.3.6.4.1 Japan Immuno-Oncology Drugs Market by Drug Type
    10.3.6.4.2 Japan Immuno-Oncology Drugs Market by Therapeutic Application
    10.3.6.4.3 Japan Immuno-Oncology Drugs Market by End User
    10.3.6.5 Rest of Asia-Pacific Immuno-Oncology Drugs Market
    10.3.6.5.1 Rest of Asia-Pacific Immuno-Oncology Drugs Market by Drug Type
    10.3.6.5.2 Rest of Asia-Pacific Immuno-Oncology Drugs Market by Therapeutic Application
    10.3.6.5.3 Rest of Asia-Pacific Immuno-Oncology Drugs Market by End User
    10.4. MIDDLE EAST AND AFRICA
    10.4.1 Middle East and Africa Immuno-Oncology Drugs Market Overview
    10.4.2 Middle East and Africa Immuno-Oncology Drugs Market Forecasts and Analysis
    10.4.3 Middle East and Africa Immuno-Oncology Drugs Market Forecasts and Analysis - By Drug Type
    10.4.4 Middle East and Africa Immuno-Oncology Drugs Market Forecasts and Analysis - By Therapeutic Application
    10.4.5 Middle East and Africa Immuno-Oncology Drugs Market Forecasts and Analysis - By End User
    10.4.6 Middle East and Africa Immuno-Oncology Drugs Market Forecasts and Analysis - By Countries
    10.4.6.1 South Africa Immuno-Oncology Drugs Market
    10.4.6.1.1 South Africa Immuno-Oncology Drugs Market by Drug Type
    10.4.6.1.2 South Africa Immuno-Oncology Drugs Market by Therapeutic Application
    10.4.6.1.3 South Africa Immuno-Oncology Drugs Market by End User
    10.4.6.2 Saudi Arabia Immuno-Oncology Drugs Market
    10.4.6.2.1 Saudi Arabia Immuno-Oncology Drugs Market by Drug Type
    10.4.6.2.2 Saudi Arabia Immuno-Oncology Drugs Market by Therapeutic Application
    10.4.6.2.3 Saudi Arabia Immuno-Oncology Drugs Market by End User
    10.4.6.3 U.A.E Immuno-Oncology Drugs Market
    10.4.6.3.1 U.A.E Immuno-Oncology Drugs Market by Drug Type
    10.4.6.3.2 U.A.E Immuno-Oncology Drugs Market by Therapeutic Application
    10.4.6.3.3 U.A.E Immuno-Oncology Drugs Market by End User
    10.4.6.4 Rest of Middle East and Africa Immuno-Oncology Drugs Market
    10.4.6.4.1 Rest of Middle East and Africa Immuno-Oncology Drugs Market by Drug Type
    10.4.6.4.2 Rest of Middle East and Africa Immuno-Oncology Drugs Market by Therapeutic Application
    10.4.6.4.3 Rest of Middle East and Africa Immuno-Oncology Drugs Market by End User
    10.5. SOUTH AND CENTRAL AMERICA
    10.5.1 South and Central America Immuno-Oncology Drugs Market Overview
    10.5.2 South and Central America Immuno-Oncology Drugs Market Forecasts and Analysis
    10.5.3 South and Central America Immuno-Oncology Drugs Market Forecasts and Analysis - By Drug Type
    10.5.4 South and Central America Immuno-Oncology Drugs Market Forecasts and Analysis - By Therapeutic Application
    10.5.5 South and Central America Immuno-Oncology Drugs Market Forecasts and Analysis - By End User
    10.5.6 South and Central America Immuno-Oncology Drugs Market Forecasts and Analysis - By Countries
    10.5.6.1 Brazil Immuno-Oncology Drugs Market
    10.5.6.1.1 Brazil Immuno-Oncology Drugs Market by Drug Type
    10.5.6.1.2 Brazil Immuno-Oncology Drugs Market by Therapeutic Application
    10.5.6.1.3 Brazil Immuno-Oncology Drugs Market by End User
    10.5.6.2 Argentina Immuno-Oncology Drugs Market
    10.5.6.2.1 Argentina Immuno-Oncology Drugs Market by Drug Type
    10.5.6.2.2 Argentina Immuno-Oncology Drugs Market by Therapeutic Application
    10.5.6.2.3 Argentina Immuno-Oncology Drugs Market by End User
    10.5.6.3 Rest of South and Central America Immuno-Oncology Drugs Market
    10.5.6.3.1 Rest of South and Central America Immuno-Oncology Drugs Market by Drug Type
    10.5.6.3.2 Rest of South and Central America Immuno-Oncology Drugs Market by Therapeutic Application
    10.5.6.3.3 Rest of South and Central America Immuno-Oncology Drugs Market by End User

    11. INDUSTRY LANDSCAPE
    11.1. MERGERS AND ACQUISITIONS
    11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
    11.3. NEW PRODUCT LAUNCHES
    11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS

    12. IMMUNO-ONCOLOGY DRUGS MARKET, KEY COMPANY PROFILES
    12.1. AMGEN, INC.
    12.1.1. Key Facts
    12.1.2. Business Description
    12.1.3. Products and Services
    12.1.4. Financial Overview
    12.1.5. SWOT Analysis
    12.1.6. Key Developments
    12.2. ASTRAZENECA
    12.2.1. Key Facts
    12.2.2. Business Description
    12.2.3. Products and Services
    12.2.4. Financial Overview
    12.2.5. SWOT Analysis
    12.2.6. Key Developments
    12.3. BRISTOL-MYERS SQUIBB COMPANY
    12.3.1. Key Facts
    12.3.2. Business Description
    12.3.3. Products and Services
    12.3.4. Financial Overview
    12.3.5. SWOT Analysis
    12.3.6. Key Developments
    12.4. LILLY
    12.4.1. Key Facts
    12.4.2. Business Description
    12.4.3. Products and Services
    12.4.4. Financial Overview
    12.4.5. SWOT Analysis
    12.4.6. Key Developments
    12.5. SANOFI
    12.5.1. Key Facts
    12.5.2. Business Description
    12.5.3. Products and Services
    12.5.4. Financial Overview
    12.5.5. SWOT Analysis
    12.5.6. Key Developments
    12.6. F. HOFFMANN-LA ROCHE
    12.6.1. Key Facts
    12.6.2. Business Description
    12.6.3. Products and Services
    12.6.4. Financial Overview
    12.6.5. SWOT Analysis
    12.6.6. Key Developments
    12.7. NOVARTIS AG
    12.7.1. Key Facts
    12.7.2. Business Description
    12.7.3. Products and Services
    12.7.4. Financial Overview
    12.7.5. SWOT Analysis
    12.7.6. Key Developments
    12.8. ABBVIE, INC.
    12.8.1. Key Facts
    12.8.2. Business Description
    12.8.3. Products and Services
    12.8.4. Financial Overview
    12.8.5. SWOT Analysis
    12.8.6. Key Developments
    12.9. PFIZER INC.
    12.9.1. Key Facts
    12.9.2. Business Description
    12.9.3. Products and Services
    12.9.4. Financial Overview
    12.9.5. SWOT Analysis
    12.9.6. Key Developments
    12.10. MERCK KGAA
    12.10.1. Key Facts
    12.10.2. Business Description
    12.10.3. Products and Services
    12.10.4. Financial Overview
    12.10.5. SWOT Analysis
    12.10.6. Key Developments

    13. APPENDIX
    13.1. ABOUT THE INSIGHT PARTNERS
    13.2. GLOSSARY OF TERMS
    The List of Companies

    - Amgen, Inc.
    - AstraZeneca
    - Bristol-Myers Squibb Company
    - Lilly
    - Sanofi
    - F. Hoffmann-La Roche
    - Novartis AG
    - AbbVie, Inc.
    - Pfizer Inc.
    - Merck KGaA,
    - Incyte
    - GlaxoSmithKline, Inc
    - Genentech, Inc
    - Johnson and Johnson Services, Inc
    TIPRE00004055
    Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

    Pricing

    Free

    20%

    customization on Pre-Booking
    Request for Sample
    Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.